BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24702143)

  • 1. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
    Nair S; Waters B
    Exp Clin Transplant; 2014 Apr; 12(2):117-22. PubMed ID: 24702143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
    Kwo PY; Ghabril M; Lacerda MA; Joseph Tector A; Fridell JA; Vianna R
    Clin Transplant; 2014 Jun; 28(6):722-7. PubMed ID: 24708229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
    Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
    Liver Transpl; 2012 Dec; 18(12):1464-70. PubMed ID: 22941516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.
    Rubin RA; Russo MW; Brown KA; Fontana RJ; Levitsky J; Vargas H; Yoshida EM; Brown RS
    Exp Clin Transplant; 2018 Apr; 16(2):182-190. PubMed ID: 27855589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
    Singhal A; Jain AB; Burke M; Black M
    Exp Clin Transplant; 2010 Sep; 8(3):214-9. PubMed ID: 20716039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.
    Farnik H; Zimmermann T; Herrmann E; Bechstein WO; Kronenberger B; Galle PR; Labocha S; Ferreiros N; Geisslinger G; Zeuzem S; Sarrazin C; Welker MW
    Liver Int; 2015 Jan; 35(1):176-83. PubMed ID: 24649882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
    Forns X; Didier S; Mutimer D; Fagiuoli S; Navasa M; Agarwal K; Berenguer M; Colombo M; Herzer K; Nevens F; Daems B; Janssen K; Ouwerkerk-Mahadevan S; Kimko H; Lathouwers E; Witek J; Van Solingen-Ristea R
    Ann Hepatol; 2016; 15(4):512-23. PubMed ID: 27236150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
    O'Leary JG; McKenna GJ; Klintmalm GB; Davis GL
    Liver Transpl; 2013 Apr; 19(4):463-5. PubMed ID: 23408534
    [No Abstract]   [Full Text] [Related]  

  • 12. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
    Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD
    Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response-guided telaprevir combination treatment for hepatitis C virus infection.
    Sherman KE; Flamm SL; Afdhal NH; Nelson DR; Sulkowski MS; Everson GT; Fried MW; Adler M; Reesink HW; Martin M; Sankoh AJ; Adda N; Kauffman RS; George S; Wright CI; Poordad F;
    N Engl J Med; 2011 Sep; 365(11):1014-24. PubMed ID: 21916639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Nair S; Satapathy SK; Gonzalez HC
    Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.